

President's Office / Bureau du président

August 25, 2006

Ms. Sylvie Dupont
Secretary of the Board
Patented Medicines Prices Review Board
Box L40
Standard Life Centre
333 Laurier Avenue West, Suite 1400
Ottawa, ON K1P 1C1

Dear Ms. Dupont:

Re: Discussion Guide for Consultations on the Board's Excessive Price Guidelines

Canada's Research-Based Pharmaceutical Companies (Rx&D) is pleased to have an opportunity to respond to the Discussion Guide on the Board's Excessive Price Guidelines.

The innovative pharmaceutical industry is proud of the strong role it plays in the Canadian economy. Rx&D companies employ more than 22 000 Canadians in high quality jobs based on innovation, with a huge growth potential for the future. Our community generates over \$4.5 billion annually for the Canadian economy. Taking into account jobs created in other sectors, our activities provide approximately 100 000 jobs – which generate some \$3 billion in tax revenues to all levels of government. We firmly believe that our industry is an important partner for setting a path for Canada to achieve great health care objectives while helping to preserve the strength of our economy.

Please find attached the hard copy of the Rx&D Response to the Discussion Guide for the Consultations on the Board's Excessive Price Guidelines. The French version will be sent as soon as the translation is completed.

Thank you again for the opportunity to comment on this important issue. Should you require additional information or for any questions you may have, please feel free to contact Philip Welford, Director of Parliamentary Affairs. He can be reached at (613) 236-0455 ext. 325 or by email at the following address: pwelford@canadapharma.org.

Sincerely,



Russell Williams
President

RW/ag
Encl.